Prostate Cancer
Filter Results
The association of statin use and biochemical recurrence after curative treatment for prostate cancer. A systematic review and meta-analysis
To investigate the association between statin use and biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP) or radiotherapy (RT) as a curative treatment, a systematic review and meta-analysis was performed.
Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
This study provides a contemporary assessment of the treatment patterns, health care resource utilization (HRU) and costs among metastatic castration-sensitive prostate cancer (mCSPC) patients in the U.S.
Patterns of Prostate-Specific Antigen Testing and Prostate Biopsies During the COVID-19 Pandemic
This study examined changes in prostate disease screening (prostatic-specific antigen [PSA] testing), prostate biopsy testing, and prostate cancer diagnoses during the COVID-19 pandemic through December 2020.
Based on biomedical index data. Risk prediction model for prostate cancer
To explore the influencing factors of prostate cancer occurrence, set up risk prediction model, require reference for the preliminary diagnosis of clinical doctors, this model searched database through the data of prostate cancer patients and prostate hyperplasia patients National Clinical Medical Science Data Center.
Why do African–American men face higher risks for lethal prostate cancer?
African–American men in the USA have a higher incidence of and mortality from prostate cancer (PCa), with a longstanding debate about the cause for these worse outcomes. This review examines differences in tumour biology and socioeconomics for African–American and Non-Hispanic White (NHW) men to answer the question ‘why AA men face higher risks for lethal PCa’ and draw a management consensus to redress the imbalance.
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer
Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course.
Multimodality treatment for localized gastric cancer: state of the art and new insights
Surgery represents the only curative approach for resectable gastric cancer.
Therapeutic targeting of the DNA damage response in prostate cancer
The present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade].
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence
The purpose of this study was to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in oligometastatic prostate cancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) and local control (LC).